Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CRDL
CRDL | US
0.93
USD-0.02
-2.22%
CRDL | US
About CRDL
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
20/03/2026
Close
0.93
Open
0.95
High
0.95
Low
0.90
Cardiol Therapeutics Inc. a clinical-stage life sciences company focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx which is in Phase II/III multi-national randomized double-blind and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19 as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville Canada.
View LessCRDL | US
Risk
51.0
Sharpe
-0.37
Luna's Score
42/100
Recommendation
Sell
Luna says (CRDL | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
64.7%1 month
51.0%3 months
49.5%6 months
55.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
13.69
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.30
Ent. to rev.
178.81
PEG
-
Other Fundamentals
EBITDA
-31.66M
MarketCap
73.72M
MarketCap(USD)
73.72M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-108.44
Short ratio
1.79
Short perc.
1.06
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.20
Range1M
0.20
Range3M
0.20
Volumes: Market Activity
Rel. volume
1.57
Price X volume
591.57K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.30 | - | Cheaper |
| Ent. to Revenue | 178.81 | - | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 13.69 | 13.15 | Par |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 49.51 | - | Lower Risk |
| Debt to Equity | 0.01 | -1.88 | Expensive |
| Debt to Assets | 0.01 | 0.48 | Cheaper |
| Market Cap | 73.72M | - | Emerging |
